DC-HIL in skin cancer.

DC-HIL 在皮肤癌中的应用。

• 批准号: 8598000
• 负责人: PONCIANO D CRUZ
• 金额: --
• 依托单位: VA NORTH TEXAS HEALTH CARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-10-01 至 2015-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8598000
• 关键词: Address; Antigen-Presenting Cells; Binding; Cells; Cessation of life; Distant; Exhibits; Fostering; Genetic; Growth; Human; Immune system; Immunity; Immunobiology; Incidence; Intraperitoneal Injections; Knockout Mice; Knowledge; Learning; Life; Malignant Neoplasms; Mediating; Medical center; Melanoma Cell; Membrane Proteins; Metastatic Melanoma; Modeling; Molecular; Morbidity - disease rate; Mus; Operative Surgical Procedures; Organ; Pathway interactions; Patients; Protocols documentation; Skin Cancer; T-Cell Activation; T-Lymphocyte; Testing; Therapeutic; Thick; United States; Veterans; fighting; killings; knock-down; lymph nodes; melanoma; mortality; novel; prevent; response; syndecan-4; trend; tumor

DESCRIPTION (provided by applicant): Skin cancer is the most common cancer in the United States and its numbers are increasing. Deaths from skin cancer are due mostly to melanoma, whose numbers are also increasing. Thin melanomas (less than 1 mm in thickness) removed by surgery are associated with normal life, but thicker melanomas (more than 4 mm) are considered to have already spread to lymph nodes or distant organs, and cannot be cured by available treatments. Having discovered melanoma to contain molecules preventing the immune system from killing the tumor, we will study how to counteract these molecules so the immune system can better fight this deadly cancer.

描述（由申请人提供）：